Researchers at Tufts Medical Center and Tufts University School of Medicine studied rates of reports of cancer as an adverse event filed. "This real-world examination shows no increased risk to patients taking ezetimibe alone or the ezetimibe/simvastatin combination to lower their lipid levels -- an issue that sparked many policy and health safety conversations," said lipidologist Hillier Karas, MD, PhD, Professor of Medicine, Tufts University School of Medicine and Associate Director, Molecular Cardiology Research Institute, Tufts Medical Center, who co- Alsheikh-Ali, MD, Institute for Clinical Research and Health Policy Studies. The study, conducted by Tufts Medical Center lipid and health policy experts, was published in the April issue of the Journal of Clinical Lipidology ).

Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows - Journal of Clinical Lipidology publishes largest study comparing cancer risk of ezetimibe and ezetimibe/simvastatin to statin therapies using FDA database - BOSTON, / - / -- A new study shows no increased cancer risk with ezetimibe mono and ezetimibe/simvastatin combination treatments, compared to cancer rates of other powerful lipid-lowering statin therapies.